Stanford’s Lucile Packard Children’s Hospital First US Pediatric Site for Technegas

Cyclopharm Breaks New Ground in US Pediatric Imaging

Cyclopharm Limited (ASX, CYC), a specialist in radiopharmaceuticals, has announced a significant milestone in its US expansion strategy. The company has entered into an agreement with Lucile Packard Children’s Hospital Stanford to implement its flagship product, Technegas, marking the first time a dedicated children’s hospital in the United States will adopt this lung ventilation imaging technology.

This development is notable not only for its pioneering nature but also for what it signals about the growing acceptance of Technegas across diverse patient groups. Traditionally used to diagnose pulmonary embolism in adults, Technegas is gaining traction for its safety profile and versatility, especially in paediatric care where minimising radiation exposure is critical.

Why Technegas Matters for Children’s Health

Technegas is a radiopharmaceutical agent that produces ultra-fine radioactive carbon particles inhaled by patients to provide detailed functional lung imaging. Its advantages include a low radiation dose and ease of use, which are particularly important for children. The technology supports high-quality imaging that can assist in diagnosing a range of respiratory conditions beyond pulmonary embolism, such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary hypertension.

Lucile Packard Children’s Hospital Stanford’s adoption of Technegas underscores the hospital’s commitment to integrating cutting-edge diagnostic tools that improve patient outcomes while prioritising safety. Stanford Medicine was among the earliest adopters of Technegas for adult patients, and this extension into paediatric care reflects confidence in the technology’s clinical value.

Cyclopharm’s US Commercial Strategy Gains Momentum

The agreement with Lucile Packard Children’s Hospital is part of Cyclopharm’s broader push to expand Technegas installations across leading academic and clinical centres in the US. By securing a foothold in a prestigious children’s hospital, Cyclopharm is positioning itself to capture a growing segment of the nuclear medicine market focused on paediatric respiratory diagnostics.

Managing Director James McBrayer highlighted the significance of this milestone, expressing optimism about supporting Stanford Medicine Children’s Health as they integrate Technegas into their clinical practice. This move could pave the way for further adoption in other paediatric hospitals and clinics nationwide.

While the announcement did not disclose financial details or specific timelines, the strategic implications are clear, Cyclopharm is steadily advancing its footprint in the US healthcare system, leveraging Technegas’s unique benefits to meet unmet needs in lung imaging.